CRBP

Company Overview — What Does Corbus Pharmaceuticals Holdings, Inc. Do?

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Corbus Pharmaceuticals Holdings, Inc. (CRBP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Yuval Cohen and employs approximately 40 people, headquartered in NORWOOD, Massachusetts. With a market capitalization of $177M, CRBP is one of the notable companies in the Healthcare sector.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Rating — Reduce (April 2026)

As of April 2026, Corbus Pharmaceuticals Holdings, Inc. receives a Reduce rating with a composite score of 33.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CRBP ranks #2,102 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Corbus Pharmaceuticals Holdings, Inc. ranks #235 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRBP Stock Price and 52-Week Range

Corbus Pharmaceuticals Holdings, Inc. (CRBP) currently trades at $9.80. The stock lost $0.52 (5.0%) in the most recent trading session. The 52-week high for CRBP is $20.56, which means the stock is currently trading -52.3% from its annual peak. The 52-week low is $4.64, putting the stock 111.2% above its annual trough. Recent trading volume was 225K shares, suggesting relatively thin trading activity.

Is CRBP Overvalued or Undervalued? — Valuation Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.17x, versus the sector average of 2.75x. The price-to-sales ratio is 32.44x, compared to 1.66x for the average Healthcare stock.

At current multiples, Corbus Pharmaceuticals Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Corbus Pharmaceuticals Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Corbus Pharmaceuticals Holdings, Inc. (CRBP) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -48.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -42.7% versus the sector average of -33.1%.

On a margin basis, Corbus Pharmaceuticals Holdings, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1527.1% (sector: -66.1%). Net profit margin stands at -1397.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 24.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRBP Debt, Balance Sheet, and Financial Health

Corbus Pharmaceuticals Holdings, Inc. has a debt-to-equity ratio of 14.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.07x, indicating strong short-term liquidity. Total debt on the balance sheet is $307,000. Cash and equivalents stand at $27M.

CRBP has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Corbus Pharmaceuticals Holdings, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Corbus Pharmaceuticals Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $5M and earnings per share (EPS) of $-5.90. Net income for the quarter was $-72M. Gross margin was 100.0%. Operating income came in at $-79M.

In FY 2025, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $6M and earnings per share (EPS) of $-5.90. Net income for the quarter was $-79M. Revenue grew -12.4% year-over-year compared to FY 2024. Operating income came in at $-85M.

In Q3 2025, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.90. Net income for the quarter was $-23M. Revenue grew -5.4% year-over-year compared to Q3 2024. Operating income came in at $-24M.

In Q2 2025, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.44. Net income for the quarter was $-18M. Revenue grew 45.0% year-over-year compared to Q2 2024. Operating income came in at $-19M.

Over the past 8 quarters, Corbus Pharmaceuticals Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $906,000 to $5M. Investors analyzing CRBP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRBP Dividend Yield and Income Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRBP Momentum and Technical Analysis Profile

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

CRBP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Corbus Pharmaceuticals Holdings, Inc. (CRBP) ranks #235 out of 838 stocks based on the Blank Capital composite score. This places CRBP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRBP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRBP vs S&P 500 (SPY) comparison to assess how Corbus Pharmaceuticals Holdings, Inc. stacks up against the broader market across all factor dimensions.

CRBP Next Earnings Date

No upcoming earnings date has been announced for Corbus Pharmaceuticals Holdings, Inc. (CRBP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRBP? — Investment Thesis Summary

The quantitative profile for Corbus Pharmaceuticals Holdings, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. High volatility (stability score 32/100) increases portfolio risk.

In summary, Corbus Pharmaceuticals Holdings, Inc. (CRBP) earns a Reduce rating with a composite score of 33.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRBP stock.

Related Resources for CRBP Investors

Explore more research and tools: CRBP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRBP head-to-head with peers: CRBP vs AZN, CRBP vs SLGL, CRBP vs VMD.